

| OMB APPROVAL | |
|--|-----------|
| OMB Number: | 3235-0287 |
| Estimated average burden hours per response: | 0.5 |

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

| | | |
|---|--|---|
| 1. Name and Address of Reporting Person* <u>Liu Joy</u> _____ (Last) (First) (Middle) C/O VERTEX PHARMACEUTICALS INCORPORATED 50 NORTHERN AVENUE _____ (Street) BOSTON MA 02210 _____ (City) (State) (Zip) | 2. Issuer Name and Ticker or Trading Symbol <u>VERTEX PHARMACEUTICALS INC / MA [VRTX]</u> | 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner <input checked="" type="checkbox"/> Officer (give title below) Other (specify below) <u>SVP, General Counsel</u> |
| | 3. Date of Earliest Transaction (Month/Day/Year) <u>08/15/2022</u> | |
| | 4. If Amendment, Date of Original Filed (Month/Day/Year) | |

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

| 1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transaction Code (Instr. 8) | | 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) | | | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) |
|---------------------------------|--------------------------------------|--|--------------------------------|---|---|------------|----------------------------|---|--|---|
| | | | Code | V | Amount | (A) or (D) | Price | | | |
| Common Stock | 08/15/2022 | | S ⁽¹⁾ | | 206 | D | \$300.26 ⁽²⁾⁽³⁾ | 13,146 | D | |
| Common Stock | 08/15/2022 | | S ⁽¹⁾ | | 698 | D | \$301.63 ⁽²⁾⁽⁴⁾ | 12,448 | D | |
| Common Stock | 08/15/2022 | | S ⁽¹⁾ | | 100 | D | \$302.35 | 12,348 | D | |
| Common Stock | 08/15/2022 | | S ⁽¹⁾ | | 700 | D | \$303.99 ⁽²⁾⁽⁵⁾ | 11,648 | D | |
| Common Stock | 08/15/2022 | | S ⁽¹⁾ | | 1,743 | D | \$305.01 ⁽²⁾⁽⁶⁾ | 9,905 | D | |
| Common Stock | 08/15/2022 | | S ⁽¹⁾ | | 300 | D | \$305.57 ⁽²⁾⁽⁷⁾ | 9,605 | D | |

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transaction Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 6. Date Exercisable and Expiration Date (Month/Day/Year) | | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | 8. Price of Derivative Security (Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) |
|--|--|--------------------------------------|--|--------------------------------|--|--|-----------------|---|--|--|---|--|
| | | | | | | Date Exercisable | Expiration Date | | | | | |

Explanation of Responses:

- Transaction made pursuant to Ms. Liu's company approved trading plan under Rule 10b5-1.
- Ms. Liu undertakes to provide (upon request by the SEC staff, the Issuer or a security holder of the Issuer) full information regarding the number of shares sold at each separate price.
- Open market sales reported on this line occurred at a weighted average price of \$300.26 (range \$300.00 to \$300.28).
- Open market sales reported on this line occurred at a weighted average price of \$301.63 (range \$301.23 to \$302.01).
- Open market sales reported on this line occurred at a weighted average price of \$303.99 (range \$303.48 to \$304.46).
- Open market sales reported on this line occurred at a weighted average price of \$305.01 (range \$304.54 to \$305.53).
- Open market sales reported on this line occurred at a weighted average price of \$305.57 (range \$305.55 to \$305.58).

Remarks:

/s/ Joy Liu 08/17/2022
 ** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.